Cited by 100Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function

Open access
Kim, B M, You, M-H, Chen, C-H, Lee, S, Hong, Y, Hong, Y, Kimchi, A, Zhou, X Z +1 more·2014·Cell Death & Disease

Abstract

The presence of tangles composed of phosphorylated tau is one of the neuropathological hallmarks of Alzheimer's disease (AD). Tau, a microtubule (MT)-associated protein, accumulates in AD potentially as a result of posttranslational modifications, such as hyperphosphorylation and conformational changes. However, it has not been fully understood how tau accumulation and phosphorylation are deregulated. In the present study, we identified a novel role of death-associated protein kinase 1 (DAPK1) in the regulation of the tau protein. We found that hippocampal DAPK1 expression is markedly increased in the brains of AD patients compared with age-matched normal subjects. DAPK1 overexpression increased tau protein stability and phosphorylation at multiple AD-related sites. In contrast, inhibition of DAPK1 by overexpression of a DAPK1 kinase-deficient mutant or by genetic knockout significantly decreased tau protein stability and abolished its phosphorylation in cell cultures and in mice. Mechanistically, DAPK1-enhanced tau protein stability was mediated by Ser71 phosphorylation of Pin1, a prolyl isomerase known to regulate tau protein stability, phosphorylation, and tau-related pathologies. In addition, inhibition of DAPK1 kinase activity significantly increased the assembly of MTs and accelerated nerve growth factor-mediated neurite outgrowth. Given that DAPK1 has been genetically linked to late onset AD, these results suggest that DAPK1 is a novel regulator of tau protein abundance, and that DAPK1 upregulation might contribute to tau-related pathologies in AD. Therefore, we offer that DAPK1 might be a novel therapeutic target for treating human AD and other tau-related pathologies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/cddis.2014.216

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kim, B. M., You, M.-H., Chen, C.-H., Lee, S., Hong, Y., Hong, Y., Kimchi, A., Zhou, X. Z., & Lee, T. H.
Affiliations
  • Beth Israel Deaconess Medical Center (US)
  • Inje University (KR)
  • Weizmann Institute of Science (IL)
Corresponding author
Lee, T H
Venue
Cell Death & Disease
Published
2014-05-22
Volume
5
Issue
5
Pages
e1237-e1237
ISSN
2041-4889 (ISSN-L)
OpenAlex
W1985025450
Cited by
98
References
62
Citations by year
2026: 5 · 2025: 6 · 2024: 14 · 2023: 9 · 2022: 8 · 2021: 7 · 2020: 10 · 2019: 5 · 2018: 11 · 2017: 4 · 2016: 9 · 2015: 8 · 2014: 2
FWCI
5.11
Type
journal article
Language
en
Open access
Locations
  • Cell Death and Disease (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
Funders
  • Alzheimer's Association
  • American Federation for Aging Research
  • National Research Foundation
  • Inje University
  • National Institutes of Health
  • National Institute on Aging (R00AG033104, P50 AG05134, T32AG023480, P50AG005134)
  • National Institute of Mental Health (R24MH068855)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
DAPK1, tau protein, tau hyperphosphorylation, Pin1, peptidyl-prolyl isomerase, Alzheimer's disease, microtubule assembly, neurite outgrowth, nerve growth factor, hippocampus, therapeutic target
MeSH terms
NIMA-Interacting Peptidylprolyl Isomerase, Age Factors, Alzheimer Disease, Animals, Brain, HeLa Cells, Humans, Mutation, Neurons, Phosphorylation, Time Factors, Transfection, Case-Control Studies, Neurites, PC12 Cells, tau Proteins, Mice, Knockout, Peptidylprolyl Isomerase, RNA Interference, NIH 3T3 Cells, Mice, Rats, Protein Stability, HEK293 Cells, Death-Associated Protein Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review